Trials / Completed
CompletedNCT01683292
Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease
An Ascending-Dose, Single-Centre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040(Inhaled Apomorphine)in Parkinson's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- South Glasgow University Hospitals NHS Trust · Academic / Other
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
In this first study of inhaled apomorphine in Parkinson's disease patients, the primary objective is to find the minimum efficacious dose of apomorphine that is useful in rescuing patients during 'off' periods. Safety, tolerability and pharmacokinetics of inhaled apomorphine will be assessed during the study.
Detailed description
Objectives:
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inhaled VR040 | |
| DRUG | Placebo for VR040 | Placebo arm |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2006-06-01
- Completion
- 2007-05-01
- First posted
- 2012-09-11
- Last updated
- 2012-09-11
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01683292. Inclusion in this directory is not an endorsement.